A Brief History of Major Events in Oncology

A Brief History of Major Events in Oncology

A structured plan for understanding a brief history of major events in oncology reveals the inflection points that reshaped one of pharma's largest therapeutic categories. For BD teams, investors, and analysts, this timeline maps the catalysts — from trastuzumab to checkpoint inhibitors to antibody-drug conjugates — that created blockbuster franchises, redirected R&D capital, and defined competitive dynamics still playing out across cancer therapeutics and diagnostics today.

Key Takeaways

• Biomarker-driven care became the dominant commercial paradigm after trastuzumab's 1998 approval for HER2+ breast cancer, establishing the template for companion diagnostics and targeted therapy co-development that underpins today's precision oncology market.
• Immunotherapy's blockbuster era began with pembrolizumab's first approval in 2014; it has since gained approvals across 17 cancer types, validating checkpoint inhibition as one of the most commercially significant mechanisms in pharma history.
• The next frontier centers on personalized mRNA cancer vaccines, with clinicians in 2025–2026 actively exploring whether patient-specific tumor vaccines can replicate the success seen in infectious disease.
• Trial catalysts drive valuation. The IRIS trial (2001), CheckMate 067 (2016), and DESTINY-Breast04 (2022) each triggered significant re-ratings of their sponsors and reshaped competitive positioning across multiple tumor types.

What happened?

The modern history of oncology is a sequence of discrete, identifiable catalysts — each one reshaping treatment standards, regulatory pathways, and commercial opportunity. CancerNetwork's timeline catalogs these milestones from 1987 through the present, offering a reference frame for understanding how the field arrived at its current inflection point.

The story begins in 1987 with the launch of the journal ONCOLOGY on March 2, which formalized a dedicated knowledge base for a discipline rapidly outgrowing general internal medicine. By the early 1990s, stereotactic body radiation therapy (SBRT) emerged from work at the Karolinska Institute, adapting techniques from stereotactic radiosurgery to deliver high-dose, precision radiation — a modality that would later become standard for inoperable early-stage lung and liver tumors.

Supportive care took a leap forward in 1991 with the approval of ondansetron, the first widely effective antiemetic for chemotherapy-induced nausea. The drug didn't treat cancer directly, but it fundamentally changed patient tolerance of cytotoxic regimens, enabling dose intensification and improving trial enrollment — a commercial catalyst that is often underappreciated in retrospective analyses.

1994 delivered two landmark events. Researchers discovered and cloned the BRCA1 gene, identifying hereditary risk for breast and ovarian cancer and launching the genetic testing industry. In the same year, the NSABP trial proved that lumpectomy plus radiation was non-inferior to radical mastectomy for early-stage breast cancer — a finding that de-escalated surgical morbidity and shifted value toward adjuvant therapeutics and radiation technology.

The precision medicine era arguably began in 1998 with the approval of trastuzumab for HER2+ breast cancer. It was one of the first oncology drugs developed against a specific molecular biomarker, and it established the commercial playbook — companion diagnostic, biomarker-selected population, premium pricing — that dozens of subsequent launches would follow.

By 2000, pediatric acute lymphoblastic leukemia survival rates climbed above 90%, a benchmark that demonstrated what protocol-driven, multi-agent chemotherapy could achieve.

The IRIS trial in 2001 produced a 68% complete response rate for imatinib in chronic myeloid leukemia, a result so striking it accelerated the drug's approval and validated the "oncogene addiction" hypothesis. Imatinib became the proof-of-concept for targeted small-molecule therapy and remains one of the most cited examples of translational oncology success.

In 2003, completion of the Human Genome Project provided the reference map for all subsequent precision oncology efforts, enabling the identification of driver mutations, the development of next-generation sequencing panels, and the eventual rise of tumor-agnostic drug approvals.

2006 brought the approval of Gardasil, the first vaccine to prevent HPV-causing cervical cancer — a preventive oncology product that created an entirely new commercial category and demonstrated that cancer could be addressed before it developed.

The immunotherapy revolution reached its commercial inflection in 2014 when pembrolizumab received its first FDA approval. It has since gained approvals across 17 cancer types, becoming one of the best-selling drugs in the world and validating PD-1/PD-L1 inhibition as a foundational mechanism. The CheckMate 067 trial in 2016 reinforced the trend, showing that combining nivolumab with ipilimumab produced superior outcomes versus either agent alone — catalyzing the combination immunotherapy paradigm that now dominates first-line development.

2017 saw the approval of 5-ALA, an imaging agent enabling real-time visualization of malignant tissue during glioma surgery — a commercially significant advance in surgical oncology that improved resection completeness.

The DESTINY-Breast04 trial in 2022 represented what investigators called a "practice-changing" moment: trastuzumab deruxtecan demonstrated significant benefit in patients with low HER2 expression — previously classified as HER2-negative — effectively expanding the addressable population for HER2-directed antibody-drug conjugates into a substantially larger patient pool.

By 2024, AI-driven pathology achieved widespread clinical adoption for predicting treatment response from tumor slides, integrating computational analysis into the diagnostic workflow and creating a new software-as-a-medical-device category within oncology.

Looking ahead to 2025–2026, clinicians are actively evaluating personalized mRNA cancer vaccines designed around individual tumor profiles — an approach that, if validated, could represent the next major market expansion in oncology.

What does this mean for BD teams and investors?

The history of oncology is, in commercial terms, a history of platform inflection points. Each milestone — from BRCA1 to checkpoint inhibitors to antibody-drug conjugates — created new addressable populations, new companion diagnostic requirements, and new competitive moats. For BD teams, the pattern is clear: the most valuable licensing targets are those that either define a new biomarker-defined population or enable a platform shift.

For investors, the timeline underscores a recurring dynamic: the biggest value creation events in oncology are not incremental improvements in existing therapies but mechanism-level breakthroughs that expand treatable populations or create entirely new treatment modalities. Pembrolizumab's expansion across 17 cancers, trastuzumab deruxtecan's penetration into HER2-low disease, and the potential of personalized mRNA vaccines all follow this pattern.

Analysts tracking competitive positioning should note that the interval between scientific proof-of-concept and commercial dominance has compressed. Imatinib went from IRIS trial results to standard of care in under two years. Pembrolizumab accumulated 17 approvals within a decade. The current exploration of mRNA cancer vaccines suggests the next wave of value creation may move even faster, particularly given the manufacturing and regulatory infrastructure built during the COVID-19 pandemic.

The NCI's historical milestones and SEER training registry provide additional epidemiological and registry infrastructure context for these commercial milestones, including the surveillance systems that enabled the survival rate improvements documented throughout this period.

How have major trial catalysts reshaped competitive positioning?

Three trials stand out for their direct impact on competitive dynamics and market valuations. The IRIS trial (2001) with its 68% complete response rate for imatinib didn't just validate a drug — it validated the entire targeted therapy hypothesis, triggering a wave of kinase inhibitor programs across the industry. The CheckMate 067 trial (2016) proved that combination immunotherapy could outperform monotherapy, reshaping first-line development strategies across every major oncology company. And DESTINY-Breast04 (2022) redefined what "HER2-targetable" means, expanding the addressable population for antibody-drug conjugates and forcing competitors to reassess their own ADC pipelines against a new biomarker threshold.

Each of these catalysts triggered measurable re-ratings — not only of the sponsoring company but of competitors with adjacent mechanisms. For analysts building oncology valuation models, these trial readouts represent the highest-signal events to track, as they frequently redefine entire drug classes rather than individual assets.

What is driving the next wave of oncology innovation?

Personalized mRNA cancer vaccines represent the most closely watched emerging category. Multiple clinical trials are now enrolling to evaluate whether patient-specific neoantigen vaccines can generate meaningful tumor responses, building on the mRNA platform infrastructure validated during the pandemic. Early-phase data from several programs have generated enough signal to sustain investor interest, though definitive efficacy readouts remain pending.

Parallel to vaccine development, advances in AI-driven pathology and computational biomarker analysis are accelerating the identification of responsive patient populations, reducing the cost and timeline of biomarker-stratified trial designs. For BD teams, companies with proprietary AI pathology platforms or mRNA vaccine delivery technology represent near-term licensing opportunities with multiple potential acquirers.

The broader NCI cancer progress timeline contextualizes these efforts within a 250-year arc of discovery, underscoring that each new modality builds on foundational infrastructure — from the SEER registry system to the Human Genome Project — that continues to enable faster translation from bench to bedside.

Frequently Asked Questions

Related coverage

• ALX Oncology to Present at 2026 Jefferies Global Healthcare Conference, Highlighting Oncology Pipeline
• ASCO ‘26: Bispecifics, ADCs, and the RAS Revolution Reshape Oncology
• Experimental pancreatic cancer drug offers new hope in major trial